Therapeutic Solutions International

What Therapeutic Solutions International does

Therapeutic Solutions International, Inc. (OTC Pink: TSOI) is a United States biotechnology holding company founded in 2011 and headquartered at 4093 Oceanside Blvd., Suite B, Oceanside, California. The company operates through a family of subsidiary companies in which clinical research is conducted via licensing agreements, with TSOI functioning as the parent holding entity. Its leadership is concentrated in a single named executive, Tim Dixon, who serves as Owner, Chairman, President and Chief Executive Officer. Headcount is reported at 1–10 employees, consistent with a lean clinical-stage operating model.

TSOI's pipeline is centered on JadiCells, a stem cell therapy candidate being developed for the treatment of COVID-19-related lung injury and currently positioned in Phase III clinical trials. The therapy is described in the input as a novel method architecture and is the company's only disclosed product. The company has signaled that positive Phase III outcomes could enable expansion of JadiCells into adjacent pulmonary indications, including long COVID syndrome. No additional pipeline assets, manufacturing capabilities, or partnership-driven product extensions were disclosed.

The business model is structured around future licensing and royalty revenue following potential regulatory approval. TSOI has not yet commercialized any product and discloses no operating revenue. Its most material capital event was a September 2022 debt-financing commitment of up to $10 million from GHS Investments earmarked for the Phase III JadiCells program, supplemented by earlier-stage tranches including a 2020 Triton Funds LLC facility and a 2015 $100,000 round. As a result, the company is best characterized today as a single-asset, clinical-stage biotech whose enterprise value is substantially a function of binary regulatory and clinical outcomes on JadiCells.

Name

Therapeutic Solutions International

Legal name

Therapeutic Solutions International, Inc.

Website

https://therapeuticsolutionsint.com

Company type

Private

Founded year

2011

Operating status

Operating

Headcount range

1–10 employees

Short description

Therapeutic Solutions International is a U.S. biotechnology holding company developing JadiCells, a stem cell therapy candidate in Phase III trials for COVID-19-related lung injury, with future licensing revenue contingent on regulatory approval.

Ownership category

akta.pro rank

Product category

Cell Therapy

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Clinical Development (Phase I–III Trial Design & Execution) (HLAIALAE)

akta.pro secondary industry

Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods) (HLAAABAL)

Keywords

• Stem cell therapy
• Cell therapy development
• Regenerative medicine
• Clinical stage biotechnology
• Pulmonary disease therapeutics

Headquarters

HQ city

Oceanside

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Licensing and Royalty Revenue: As a biotechnology holding company, Therapeutic Solutions International conducts clinical research through subsidiary companies via licensing agreements. Revenue generation is expected through licensing of therapeutic products following regulatory approval.

Go-to-market motion1 record

Core offering

Therapeutic Solutions International is a biotechnology holding company that develops therapeutic products through a family of subsidiary companies operating under licensing agreements. Its lead program, JadiCells, is a stem cell therapy candidate in Phase III clinical trials targeting COVID-19-related lung injury, with planned expansion into long COVID and other pulmonary diseases.

Product overview

Therapeutic Solutions International, Inc. is a United States-based biotechnology holding company that operates through a family of subsidiary companies via licensing agreements. The company's primary product pipeline centers on JadiCells, a stem cell therapy currently in Phase III clinical trials for COVID-19-related lung injury, with potential expansion into other pulmonary diseases including long COVID.

Differentiator

Problem solved

Functional benefit

Products and services

• JadiCells JadiCells is an investigational stem cell therapy product targeting COVID-19-related lung injury, currently in Phase III clinical trials and intended for patients with severe COVID-19 respiratory complications, with planned expansion into long COVID and other pulmonary disease indications.

Quantifiable outcome

• Phase III clinical trial success could lead to regulatory approval for COVID-19-related lung injury treatment

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Scale indicators2 records

Recent moves5 records

Expansion highlights4 records

Direct peers

• Capricor Therapeutics: Cell therapy developer (dermacell/francisco-based CAP-1002) that has explored COVID-19-related indications. Comparable as a small-cap, late-stage clinical cell therapy peer.
• Pluristem Therapeutics: Cell therapy company using placenta-derived adherent stromal cells, with development programs in pulmonary and inflammatory indications including COVID-19 ARDS. Comparable modality, route of administration, and indication space.
• Brainstorm Cell Therapeutics: Develops autologous cell therapies (NurOwn) for neurodegenerative and other indications. Comparable as a small clinical-stage cell therapy peer focused on a single modality-driven pipeline.
• Mesoblast: Clinical-stage cell therapy company that has developed remestemcel-L, including for inflammatory lung conditions including COVID-19-related ARDS. Highly comparable given similar modality, indication overlap, and late-stage development status.
• Athersys: Developed MultiStem cell therapy for ARDS and other inflammatory conditions, including COVID-19-related respiratory indications. Direct comparable in stem-cell-based treatment of lung injury.
• Lineage Cell Therapeutics: Clinical-stage cell therapy company developing allogeneic cell transplants for serious diseases, including pulmonary programs. Comparable given shared cell therapy modality and similar small-cap clinical-stage profile.

Emerging players

• CardioCell: Develops stem cell therapies for cardiovascular and inflammatory conditions, including pulmonary hypertension. Comparable as a small cell therapy peer with overlapping modality and indication themes.
• VistaGen Therapeutics: Late-stage clinical biotech with a small pipeline of novel therapies. Comparable as a small publicly-traded clinical-stage biotech at similar capitalization and stage.
• Helius Medical Technologies: Small clinical-stage company developing novel therapeutic technologies for neurological symptoms. Relevant as a small-cap, single-asset clinical peer, though indication focus differs.
• Celularity: Cellular medicine company developing placenta-derived cell therapies including for infectious disease and inflammatory indications. Partial overlap in cell therapy platform and pulmonary/inflammatory indications.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat2 records

Key risks6 records

Key highlights5 records

Customer concentration

• LinkedInlinkedin.com/company/therapeutic-solutions-international-inc

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds3 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Therapeutic Solutions International